Short Interest in NewAmsterdam Pharma (NASDAQ:NAMSW) Decreases By 40.8%

NewAmsterdam Pharma (NASDAQ:NAMSW) was the recipient of a large decline in short interest during the month of June. As of June 15th, there was short interest totaling 42 shares, a decline of 40.8% from the May 31st total of 71 shares. Based on an average daily volume of 1,378 shares, the days-to-cover ratio is presently 0.0 days.

NewAmsterdam Pharma Stock Performance

NASDAQ:NAMSW remained flat at $23.44 during midday trading on Friday. The company’s 50 day moving average price is $22.20 and its 200 day moving average price is $22.21. NewAmsterdam Pharma has a fifty-two week low of $8.41 and a fifty-two week high of $30.45.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in NewAmsterdam Pharma stock. Aristeia Capital L.L.C. acquired a new position in NewAmsterdam Pharma (NASDAQ:NAMSW) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,708 shares of the company’s stock, valued at approximately $397,000.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.